Recent research has validated the potential role of NEX in cancer treatment by examining cytotoxic molecules on NEX such as DNAX accessory molecule-1 (DNAM1) and demonstrating the anti-tumour effect of NEX in NSCLC [124,125]. Here, CD226 is linked to non-small cell lung carcinoma.